Clinical trials
Hepatocellular Carcinoma Recurrent clinical trials
Below are recruiting hepatocellular carcinoma recurrent clinical trials, each written for real people, not researchers. We’re tracking 169 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05407519RecruitingPhase 2
Tislelizumab and sitravatinib after liver cancer surgery to prevent relapse
This trial studies whether combining two medicines (tislelizumab and sitravatinib) given after curative liver cancer surgery can help prevent the cancer from coming back. It is for people with liver cancer at high risk of recurrence, who have fully recovered from surgery and have no spread beyond the liver.
Hefei, AnhuiAges 18–70 - NCT05489289RecruitingPhase 3
AK104 to prevent HCC coming back after surgery
This trial tests whether AK104, taken after liver cancer surgery, can lower the chance that the cancer returns. It is for people with high risk of recurrence but no remaining cancer after surgery.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06236568Recruiting
Liver transplant study for liver cancer patients
This study tests a special way to preserve donated livers before transplant to see if it reduces the chance of liver cancer coming back after surgery.
Modena, MOAges 18 years+ - NCT06327269RecruitingEarly Phase 1
Targeted therapy after liver transplant for high-risk liver cancer
This trial tests a targeted therapy (lenvatinib) given after a living-donor liver transplant to prevent high-risk liver cancer from coming back. It is for people whose cancer is aggressive or did not respond well to previous treatments.
Kaohsiung CityAges 18–75 - NCT06454578RecruitingPhase 2
Study of adebrelimab plus apatinib after liver cancer surgery
This trial is testing a combination of two drugs (adebrelimab and apatinib) after liver cancer surgery to see if it can lower the chance of the cancer returning. It is for people whose tumors had high-risk features.
Jinan, ShandongAges 18 years+ - NCT06577272Recruiting
Predicting cancer return after tumor ablation
This study looks at people with liver cancer who are treated with a procedure called radiofrequency ablation (RFA). It aims to create a tool that can predict the chance of the cancer coming back after treatment.
Hangzhou, ZhejiangAges Any age - NCT06999837Recruiting
PSMA PET/CT scan for liver cancer (HCC)
This study tests a new type of PET/CT scan (called PSMA) that may help doctors see liver cancer (HCC) better. The scan takes detailed images to track how the cancer behaves, which could help choose the best treatment.
ClichyAges 18 years+ - NCT05024214RecruitingPhase 1/Phase 2
Test of envafolimab plus lenvatinib for advanced solid tumors
This trial studies whether combining envafolimab (an anti-immune cancer medicine) with lenvatinib (a targeted pill) can shrink or control advanced cancers that have stopped responding to standard care. It may help people whose tumors are not curable with usual treatments, by testing a new combo and finding safe doses.
Bengbu, AnhuiAges 18 years+ - NCT06687941RecruitingPhase 1
Trial of AST-201 for GPC3-positive advanced solid tumors
This trial tests a new drug called AST-201 for people with advanced solid tumors that have a specific protein (GPC3). The study aims to see how safe and well-tolerated the drug is, and how the body processes it.
Goyang-si, Gyeonggi-doAges 19 years+ - NCT07348211RecruitingPhase 1
Study of SIM0610 for advanced solid tumors
This trial tests a new drug called SIM0610 for people with advanced solid tumors that have stopped responding to standard treatments. The study aims to see if the drug is safe and effective.
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT06537193Recruiting
Shorter MRI vs CT scan to check for liver cancer return
This trial compares a shorter MRI using a special dye to a CT scan for detecting liver cancer recurrence in people who have been cancer-free for at least two years after surgery or local treatment.
Seoul, Songpa-gu , 88, Olympic-ro 43-gilAges 20 years+ - NCT07075120RecruitingPhase 1
Immunotherapy and radiation for advanced liver cancer
This trial tests a combination of two immunotherapy drugs (ipilimumab and nivolumab) plus targeted radiation (SBRT) for people with liver cancer that is advanced but has not spread outside the liver. The goal is to see if this approach can shrink tumors and make them easier to remove with surgery.
Honolulu, HawaiiAges 18 years+ - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
Phoenix, ArizonaAges 18 years+ - NCT07328009RecruitingPhase 2
Personalized liver cancer treatment trial
This trial tests new treatment plans for people with advanced liver cancer that has worsened after initial therapy. The goal is to find more effective, personalized options based on how your cancer responds.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06349044Recruiting
Radiation and immunotherapy with or without probiotics for advanced digestive cancers
This trial tests if adding a probiotic (Lactobacillus rhamnosus M9) to standard radiation and immunotherapy can help people with advanced digestive system cancers. It aims to see if the combination is more effective and safer than the standard approach alone.
Hangzhou, ZhejiangAges 18–75 - NCT07327788RecruitingPhase 2
Study of QL1706, bevacizumab, and chemo infusion for liver cancer with portal vein clot
This trial tests a combination of three treatments for people with advanced liver cancer that has spread into the main portal vein. The goal is to see if this therapy can shrink tumors and improve outcomes.
Guangzhou, GuangdongAges 18 years+ - NCT07419841RecruitingPhase 1
A study of CTX-10726 for certain advanced cancers
This trial tests a new drug called CTX-10726 in people with advanced kidney, liver, stomach, or uterine cancer that has not responded to standard treatments. The goal is to see if the drug is safe and tolerable.
Omaha, NebraskaAges 18 years+ - NCT05468359RecruitingPhase 1/Phase 2
Testing four medicines in children and teens with hard-to-treat tumors
This early-phase trial studies how safe and effective a combination of four medicines is for children and teens with certain solid tumors that have come back or cannot be controlled with standard treatment. It may help by improving tumor control, while also carefully tracking side effects.
Germantown, TennesseeAges Up to 30 years - NCT07594964RecruitingPhase 1
Safety Study of XH001 Injection for High-Risk Recurrent Solid Tumors
This early-stage trial tests a new injection called XH001 as an additional treatment after surgery for patients with high-risk cancers that have come back. The goal is to check if it's safe and whether it helps prevent the cancer from returning again.
BeijingAges 18–70 - NCT07159048Recruiting
Heat therapy for liver tumors
This trial tests a heat-based treatment for liver cancer tumors that uses multiple methods to destroy cancer cells. It may help people with liver tumors that haven't spread and who are healthy enough for treatment.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06569498Recruiting
Triple therapy before surgery for liver cancer
This trial tests whether a combination of three drugs given before surgery can help shrink liver cancer and improve outcomes for patients whose tumors can be removed. It is for people with intermediate-stage liver cancer that is still operable.
Fuzhou, FujianAges 18–75 - NCT06646198RecruitingPhase 2
TIPS with half-dose Donafenib for liver cancer with portal hypertension
This trial tests a treatment that combines a procedure called TIPS with a targeted therapy drug (Donafenib) at half strength. It is for people with advanced liver cancer that has spread into the portal vein and caused high blood pressure in the liver (portal hypertension). The goal is to see if this combination can help control the cancer and reduce complications.
Guangzhou, GuangdongAges 18–75 - NCT05917431RecruitingPhase 2
Radiation plus immunotherapy and targeted pills for liver cancer
This Phase 2 trial studies whether a combination of SBRT (focused radiation) plus tislelizumab and regorafenib can control unresectable or limited-spread liver cancer. It may help by attacking tumors in the liver and immune system to improve shrinkage and control of disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07018947RecruitingPhase 2
Atezolizumab and bevacizumab before and after surgery for liver cancer
This trial tests whether adding two drugs (atezolizumab and bevacizumab) before and after surgery can lower the chance of liver cancer coming back in people with high-risk HCC. You must be eligible for surgical removal of your tumor.
Badalona, BarcelonaAges 18 years+
Hear when a new Hepatocellular Carcinoma Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatocellular carcinoma recurrent?
- Yes. Clin2 currently lists 169 recruiting hepatocellular carcinoma recurrent studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatocellular carcinoma recurrent trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatocellular carcinoma recurrent trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.